Trial reportScientific reports2018
Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing.
Trial report in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- The pharmacokinetics and its covariates of rituximab in different clinical populations: a systematic review and narrative synthesis.European journal of clinical pharmacology · 2026Pooled it
- Efficacy and safety of low dose rituximab in pemphigus: an updated systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- An update on the clinical evidence that supports biosimilar approvals in Europe.British journal of clinical pharmacology · 2018Pooled it
- Trial
- Real-World Experience With Single Ultra-Low Dose Rituximab for Remission Induction in Pemphigus.The Journal of dermatology · 2026Article
- Is It Time to Reconsider Rituximab Dosing Regimens for Pemphigus Vulgaris?Antibodies (Basel, Switzerland) · 2024Article
- Very low doses of rituximab in autoimmune hemolytic anemia-an open-label, phase II pilot trial.Frontiers in medicine · 2024Article
- Comparison of the efficacy of steroid-free versus classic steroid-containing regimens in primary membranous nephropathy.Frontiers in pharmacology · 2024Article
- Kinetic-pharmacodynamic model to predict post-rituximab B-cell repletion as a predictor of relapse in pediatric idiopathic nephrotic syndrome.Frontiers in pharmacology · 2024Article
- Role of Rituximab in the Treatment of Pemphigus Vulgaris: Patient Selection and Acceptability.Patient preference and adherence · 2022Review
- Post-marketing dosing changes in the label of biologicals.British journal of clinical pharmacology · 2019Article
- Article
- Pemphigus Foliaceus-Repeated Treatment With Rituximab 7 Years After Initial Response: A Case Report.Frontiers in medicine · 2018Article
- Ultra-Low Dosage Regimen of Rituximab in Autoimmune Blistering Skin Conditions.Frontiers in immunology · 2018Article
- Updates on the Management of Autoimmune Bullous Diseases.Indian dermatology online journalReview
- Ultra-Low-Dose Rituximab in Pemphigus Vulgaris: How Low is the Lowest?Indian dermatology online journalArticle
- Rituximab in Pemphigus: Road Covered and Challenges Ahead.Indian dermatology online journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are no dose-finding trials available for rituximab that could guide dosing in non-malignant diseases. We hypothesized that currently used doses (≥375 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.